Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (12.8), the stock would be worth ¥19.05 (21% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 16.2 | ¥23.99 |
0%
|
| 3-Year Average | 12.8 | ¥19.05 |
-21%
|
| 5-Year Average | 10.3 | ¥15.28 |
-36%
|
| Industry Average | 23.8 | ¥35.27 |
+47%
|
| Country Average | 20.8 | ¥30.87 |
+29%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Jiang Zhong Pharmaceutical Co Ltd
SSE:600750
|
15.2B CNY | 16.2 | 16.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 51.1 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 23.4 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 21 | 27.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.9B CHF | 15.3 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 18.5 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 10.7 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 17 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 10.6 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
Jiang Zhong Pharmaceutical Co Ltd
Glance View
Jiang Zhong Pharmaceutical Co Ltd. has etched its mark in the bustling landscape of China's pharmaceutical industry by embracing a strategic blend of traditional Chinese medicine (TCM) and modern medical practices. Founded in 1969 and headquartered in Wuhan, this company has steadily navigated the dynamic tides of China's healthcare sector. Jiang Zhong specializes in producing and marketing a wide array of TCM products, which are deeply rooted in ancient Chinese medical philosophies and practices. These offerings cater to various health needs, including gastrointestinal management, respiratory treatments, and nutritional supplements, which resonate well with China's rich cultural heritage of natural health solutions. The company's commitment to quality and efficacy has allowed it to carve out a substantial market niche where tradition meets innovation. Making money for Jiang Zhong Pharmaceutical Co Ltd. revolves around its robust distribution networks and strong brand presence across key domestic markets. The company has invested in extensive research and development initiatives to ensure its product line remains relevant and effective in addressing modern health challenges, alongside its traditional product offerings. By leveraging a diverse marketing strategy that includes partnerships with healthcare institutions, direct consumer promotions, and digital platforms, Jiang Zhong successfully taps into both local and international markets. Additionally, the company enhances its profitability through economies of scale and strategic cost management, allowing it to maintain competitive pricing while achieving substantial revenue growth. This balanced approach of blending tradition with innovation continues to fortify Jiang Zhong Pharmaceutical's position as a respected entity in both TCM and broader pharmaceutical realms.